EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

September 13, 2023

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 76 min

Earnings Call Speaker Segments

Nicola Fiore

unknown
#1

All right. Good afternoon, everyone, and welcome to the conference call covering EL.En.'s financial results for the first half of 2023. This call is being recorded, and so there will be a chance to ask questions at the end of it. Joining me are Andrea Cangioli, EL.En CEO, and Enrico Romagnoli, EL.En, Chief Financial Officer and Investor Relator. Before we start, please be aware that management has a remark concerning future expectations, plans and prospects as well as forward-looking statements. Statements on this call that are sustained, including those addressing the company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Such forward-looking statements involve known or unknown risks, including general economic and business conditions and the condition of the industry in which the company operates, and may be affected if assumptions turn out to be inaccurate. As a consequence, no forward-looking statements can be guaranteed, and actor future results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding the content nor to update the forward-looking statements to reflect events or circumstances that may occur after the date hereof. But at this moment, I want to give the word to Andrea Cantele.

Nicola Fiore

unknown
#2

Andrea, please go ahead.

Andrea Cangioli

executive
#3

Thank you, Nicola. Thank you, Bianca. And thanks to everyone joining this conference call following the release of the 6 months financials. Enrico is here with me, and we'll give a brief overview in general, touching on some numbers as well, and then Andrea will come back — we'll go deeper into the details of the figures for this first 6 months of 2023. Starting with overall performance, the financial results as a whole remain very strong and positive, with consolidated revenues up roughly 6% and consolidated EBIT tracking the record of 2022 levels with a slight delay of 6%. With respect to the guidance we provided earlier, we are in line on revenues and slightly also on EBIT. As the trend of the first quarter had already highlighted, the second quarter confirmed that in this 2023, our performance is excellent in certain areas. Most of our business areas, I'd say, and disappointing in one single business area. To date, I mean until June 30, 2023, the trend in sales and profitability exceeded the record benchmark of 2022 in the medical sector and in most of the activities of the industrial sector with the one exception of the ship metal laser cutting business on the Chinese territory.

Andrea Cangioli

executive
#4

When it comes to revenue, the strong results in the well-performing areas do more than offset the revenue decline in the Chinese areas, which produces overall revenue growth of 6%. Regarding EBIT, better performance in several areas was not enough to keep the consolidated result from posting a slight decrease compared with 2022. In the medical business, demand stayed at healthy levels across all the market segments. We are now seeing a normalization phase. After the hype of the post-pandemic phase, the market environment is slowly going back to the normal standards we were used to before the pandemic. The challenges and priorities we face at present are no longer driven by the desperate effort to obtain the materials required to meet the buoyant demand that was pushing our order books up to record levels; instead, they focus once more on defining and executing product development and market access strategies meant to let the group benefit from the overall positive trend expected in these markets. Markets and customers need to be stimulated again through intense marketing activities, worldwide on-site visits, trade fairs and congresses. The size of the open orders book is adequate for a good sales performance, but it does not imply extended delivery turns as it did during 2022.

Andrea Cangioli

executive
#5

When we think about where our markets can grow over the long term, that wider view is what guides our strategies, our investments, and our targets. Right now, this phase is also shaped by uncertainty in the economic trend stemming from inflation, from higher interest rates, and from unresolved international matters — the war in Ukraine and how relations between China and Western countries develop. The uncertainty coming from these issues is not helping capital goods markets, which, since they involve investments that typically carry a return over several years, are obviously more comfortable with a steadier economic environment. Let me add as well that our research and development spending remains strong so we can keep competing through innovation in what we offer, and through an appealing proposition for our customers, because the ingenuity and the innovativeness of our buffer tend to draw customers to our products even in periods when the economic trend is not generally so strong. Turning to the Industrial business, LeaseCo kept performing very well in Western countries and poorly in China. Alita, which manufactures at its facility nearby here in Prato, later systems for the Italian and worldwide markets with the exception of China, once again saw record revenues, up 30%, on the good performance of both the Italian and the international markets.

Andrea Cangioli

executive
#6

Order bookings came in strong, which is what we anticipated, with a growing share coming from international markets as well as from higher-power systems — and that's encouraging, since it points to better margins on sales. So we expect the trend to stay positive through the remainder of the year, though growth will be slower, because the 2022 comparison base gets tougher in the second half. On a related note, we're at FabTech in Chicago right now — the leading trade show for U.S. manufacturing. I'm glad to say our booth has been a big success, and we're showing one of our high-performance laser cutting systems there for shipment. The main issue we face today in the Chinese markets is the decline in margins on sales, and that's the key metric we need to improve in order to turn around the disappointing results we're seeing now. As we shared, in our outlook for 2023 we're expecting a strong rebound in the Chinese market, which took a heavy hit in 2022 from the zero COVID approach and the lockdown strategy that followed, which cut China off from the rest of the world and hurt both day-to-day operations and the business line far more in 2022 than had been the case during the acute initial phase of early 2020.

Andrea Cangioli

executive
#7

The rebound of the Chinese economy is not taking place, as is now clear and well discussed and analyzed also outside of the technical debate of the financial Loos Papers, and the economic environment is facing unprecedented headwinds. Also, the support expected by the government policies has been lagging in the 6 months or turd to be defensive rather than expensive. The environment is not helping us, but it wouldn't be fair to blame only to the economic environment for our poor performance. We are experiencing a fierce competition on the domestic market, which is depleting the already slim sales prices and impacting on the sales margin and subsequently moving upward the breakeven point and make it harder to reach the leverage effect that based on the wide capacity investments over the last years and the increased sales volume and amount had allowed the improvements in the local financial results. The isolation that force of China, our Italian managers in the technical and sales departments turned out to have inhibited the cooperation and cross-virtualization processes that allow the Italian and Chinese knowledge bases to be effectively shared for the benefit of both parts. And the rapid changes in the Chinese markets would have required a rapid and coordinated response that only in recent months, we are now able to define and organize.

Andrea Cangioli

executive
#8

Naturally, the situation in China is influencing the IPO as well, since with the present financial results it wouldn’t be possible to reach meaningful metrics regarding the cost of capital for the IPO share capital increase. That process remains live at the moment and is paused while the congress compliance procedures are set to be restarted once the results indicate that a successful IPO is possible. I’ll give you some figures for the literate business unit during these 6 months of 2022. Revenue stayed flat at EUR 126 million, and within that China declined from EUR 72 million to EUR 55 million. The latter figure also includes the inorganic contribution from KBF, about EUR 6 million. And KBF is the Shenzhen based company specializing in Laser site for manufacturing batteries for electric vehicles that we acquired at the end of year 2022. EBIT for the cutting division fell during the 6 months from EUR 6 million to EUR 1.1 million, despite the excellent performance of <<inaudible>>. As I said, I confirm that we are proactively working on cost reduction, revenue generation, product configuration and market coverage so that we can rapidly reverse the negative trend in our Chinese business.

Andrea Cangioli

executive
#9

I won't go deep into the figures, but I do want to say a few words about the restatement of the equity and net financial position balances that we reported in our press release. The issue concerns the share capital increase that was subscribed on penalizing terms between October and December 2022 by 4 Chinese private equity funds. This follows the practice adopted by Chinese companies and the accounting treatment for capital increases in preparation for an IPO, along with the guidelines of the CSRC, the supervisory authority for Chinese stock markets. Those pending amounts were recorded within equity, despite the existence of the customer — customary withdrawal option that investors hold if the IPO process fails. We now recognize the prevalence of IFRS principles and are restating within financial debt most of the bidding amounts, with the exception of the amounts tied to one of the investors that executed a waiver of the option closes. In addition, the interest that would be owed to the investor in the event of withdrawal, 6% a year, has been factored into the balance sheet balances and the profit and loss statement. What matters to underline is that this technical adjustment in terms of financial reporting has no connection with the poor performance of our Chinese subsidiaries.

Andrea Cangioli

executive
#10

That restatement also adds to the erosion of our net financial position, and that's one of the items I intended to address on this call. In any case, the period-over-period movement in the net financial position isn't impacted by our statement, and it shows the balance dropping by approximately EUR 65 million, split evenly across the first 2 quarters. Because the second quarter included dividend payments totaling EUR 18 million, current operations performed much better than in the first quarter, yet they remain cash negative and that has to be turned around, or ideally improved upon. We expect it to reverse in the following quarter. Net working capital absorbed most of the cash, rising sharply across the 6 months. Among the elements of net working capital, the trade receivables roll-out was physiologic, with the balance up by under 5%, consistent with higher sales volume, and so with no further movement in the days of sales outstanding metric. Inventories and trade payables were the biggest drivers of the increase. The former rose by EUR 23 million, while the latter fell by EUR 24 million.

Andrea Cangioli

executive
#11

The origins and drivers of this pattern trace back to 2022, when demand surged and we faced a frantic scramble to secure materials in time to enable the <<inaudible>> — someone is speaking there. The roots and causes of this pattern go back to 2022, with demand booming and the intense difficulty of sourcing materials promptly so that we could offer reasonable delivery terms to customers, and also in the proportional white part purchasing plant support of the expected 2023 sales expansion. During 2022, we intentionally raised the current purchase volume, the purchase volume commitments, and we shortened the average payment terms to vendors so as to secure a competitive advantage in a market where being able to deliver on time was the exception. In the opening months of 2023, we reaffirm this strategy. Now that supply chain constraints are being removed and lead time seem to return to normality, we are returning to the normal purchasing standards. Meanwhile, we saw a progressive increase of inventories, including a progressive increase of what we could define safety inventory. Upon expiration of the payment terms, winter vendors were paid, why? Also due to the normalization of the market cycle, it will take some time to liquidate the so-called safety inventory.

Andrea Cangioli

executive
#12

You should be aware that, based on everything we know right now, this safety stock does not carry a greater obsolescence risk. That said, in some situations it may take some time before it gets consumed in line with demand swings for particular product lines, though eventually that will be worked into the production processes and cost of goods. On inventory, we are also seeing a rise at the end of June in finished products — in finished goods — as we get ahead on manufacturing for certain long-term plant customer orders so as to optimize how we manage production capacity across the year. Also, beyond the 3 main components of net working capital — trade receivables, inventory and trade payables — a meaningful rolling cash absorption came from deposits from customers, and with 2 suppliers we jointly recorded a cash absorption of EUR 10 million in the 6 months, mainly reflecting the reduced amount of the order books in China and of the order books in Italy, regarding the order books bare down payments, which means the order books related to vessel were 4.0 tax cuts. That wraps up my general introduction. Please, Enrico, go ahead with your report.

Enrico Romagnoli

executive
#13

Alright, thank you, Andrea. And as usual, I'll walk you through some specifics on the most recent financials. On this slide you can see revenue growth of 5.7%, reaching EUR 345.6 million, with a bigger gain in medical, at 8.5%, than in industrial, at 2%. Gross margin came in at EUR 131.5 million, 8% higher than the EUR 121.8 million posted in the first half of 2022. In medical, the sales margin showed a modest improvement, driven mainly by a more favorable product mix, and also by price increases that offset inflation's impact on COGS. In industrial, by contrast, the sales margin declined, chiefly because of the difficulties in the China market that Andrea already mentioned — a market made more competitive by the 2022 crisis, from which it is still struggling to recover. Operating expenses rose as a share of sales, from 8.5% to 8.9%. The principal drivers are sales and marketing costs for trade shows and congresses, incurred by both the medical and industrial businesses. Staff costs went up by EUR 8.2 million, though their impact on sales edged up only slightly. Expenses for stock options and share-based payments to employees also contributed to the higher costs.

Enrico Romagnoli

executive
#14

During 2023, that figure stood at EUR 1.6 million, versus EUR 0.5 million across the opening six months of 2022. By the close of June, the group counted more than 2,200 employees. For the largest part, 91 of those positions came from the staff of newly acquired KBF, a Shenzhen-based company picked up at the end of the year. As for the remaining new hires, they were mostly at Asclepion in Germany, a business that expanded 29% in the first half, and at Quanta System, which grew 20% during the first half of 2023. EBITDA came in at EUR 45.7 million, a decline of 3.3% from the EUR 47.2 million recorded as of June last year. The EBITDA margin stood at 15.2%, lower than the 14.4% seen for 2022. Depreciation and other accruals rose, reflecting investments made over recent years as well as a bad debt reserve. First, warranty expenses came down, largely because of slower turnover in China. The overall effect on sales is roughly flat. EBIT posted a positive balance of EUR 38.9 million for the first half, below the EUR 41.4 million of 2022, with its impact on turnover falling from 12.7% to 11.2%.

Enrico Romagnoli

executive
#15

Keep in mind that 2023 EBIT takes a hit from the hefty notional cost tied to stock options and share-based payments, as I mentioned earlier — a senior to employees Director and collaboration — and collaborators, amounting to EUR 1.2 million versus 2022. Pretax income was affected by a negative 4x, chiefly from the U.S. dollar, and interest expense is computed on the virtual liability that brought in Petalidi Jan at the close of 2022, posting a positive balance of EUR 37.8 million, a decrease of EUR 41.6 million. Net income came in at EUR 25.7 million, lower than last year's EUR 28.4 million. On the balance sheet side, this balance sheet, as you can observe in calendar 2022 should already have the number restated, you can see on this slide the effect of the restatement that hit the net financial position and, by the same amount, total net equity of EUR 15.2 million, with no change regarding net capital employed. We can observe that the principal decrease in the net financial position — lies in the net financial position, which went from EUR 75 million at the start of the year to EUR 10 million by the end of June 2023.

Enrico Romagnoli

executive
#16

When it comes to cash flow, the stages where working capital is significantly assumed—as Andrea mentioned—continue through group operating activities, but the second quarter shows a slowdown, and a reversal is anticipated for the latter half of the year. Working capital growth absorbed EUR 59 million of cash during the half year, 26 of which came in the first quarter, while shifts in advances to customers, supplier balances, tax payable, and tax credit freed up another EUR 50 million across the 6 months. Fixed investment came to EUR 8.5 million, lower than a year earlier in line with the forecast, and the dividend payment of EUR 18.9 million is an annual outlay that hits only the second quarter. The substantial inflow from current profitability, EUR 27.8 million in the half year, helped constrain the cash absorption caused by the items just discussed. Sustaining solid current profitability, the trend reversal, working capital expansion, and no dividends left to pay should permit a marked improvement in net financial position by the close of the financial year. Turning to the breakdown by business.

Enrico Romagnoli

executive
#17

Medical accounted for 57% of total sales at the end of June, while industrial made up 43. The strong performance in sales of systems for surgical use stands out, nearing 30% growth, in line with forecasts and with the gradual recovery following the slowdown during the COVID period. Therapy and aesthetics are growing as well, and the residual and other segment is expanding very quickly, thanks to a renewed interest in dentistry systems. Turnover for aftersales service and consumables shows higher growth than equipment turnover, thanks to growth in the installed base, which naturally brings a greater volume of technical assistance on the system and use of consumables, especially in urology, where every procedure requires optical fiber. Turnover growth in the asset sector is around 2%. And after years of progressive rapid growth, which led it to make up almost 85% of sales in the industrial sector, the cutting sector is holding its turnover steady through the first half of 2023. This stability actually comes from 2 profoundly different results: still brilliant and growing very rapidly with Catalent in the Western market — Italy and Europe and the United States — and slowing down in China's territory, which represents approximately half of the group's sales in the sector and where turnover decreased on the order of 20%.

Enrico Romagnoli

executive
#18

Leasing marketing is still holding up, coming in above 33% and rising during the first half, thanks to the strong showing from both List in Market for unification and Atlas for decoration and special processing with CO2 lease sources. Revenue from industrial sources is basically flat. Meanwhile, the drop in revenue for after-sales service and consumables is largely attributable to the market slowdown in China. Looking at the breakdown by area, the sales trend by macro geographical area across the 2 sectors shows the best overall performance in the medical sector, particularly in foreign markets, while in the industrial sector, the strong sales performance in Italy and in new local stands in contrast to a slowdown in the rest of the world, driven by lower sales reported in the cutting set by the Chinese company. Andrea, if you'd like, you can comment on the guidance for the year.

Andrea Cangioli

executive
#19

Yeah, yeah, it's open now. As for the 2023 guidance, we set our targets as we always have to, given the complicated conditions we work in — especially right now when it comes to the Chinese market. For the full year 2023, we're confirming the forecast of a modest rise in consolidated revenues versus 2022. On EBIT, we're looking at the close of the year to hold the same percentage margin as, or a delay relative to, the 2022 figures. That wraps up our prepared remarks, and we're ready to take your questions, if there are any.

Bianca Fersini-Mastelloni

unknown
#20

Andrea, there are a few questions we have. The first comes from Giovanni Selvetti at Berenberg.

Giovanni Selvetti

analyst
#21

Okay, the first thing is about the aesthetic division. EUR 114 million for the semester means Q2 sales came in at 58%, and that's a year-on-year decline of about 1.5% to 2%. Given how bullish some of your competitors in aesthetics have been, I'm wondering whether you believe — I know 2022 was exceptionally strong — but is there something you're seeing there, do you feel you're losing a bit of market share? Or how do you read the slowdown in Q2? And most importantly, can we expect that same growth rate for the aesthetic division in the second half of the year? The second question is obviously about China — I know it's hard to have a view on how things there will develop, and I know that's not up to you. But I'm wondering what actions you're taking to stop the bleeding, really, going forward. I'm not sure I've got this right, but I think Enrico mentioned additional hirings in China — I was thinking of asking whether it's reasonable to expect some firing or some cost cutting if the top line doesn't improve?

Giovanni Selvetti

analyst
#22

And then, as a last question about China, is it possible to roughly quantify the loss that China brings at the consolidated level? And the third one concerns the net financial position at debt. So besides their announcement of the capital increase in the Chinese private equities, there appears to have been a steady absorption of working capital recently. And while I sort of understand it when you have supply chains where you may need to pay your supplier earlier, or in advance, now that things have normalized, I was trying to figure out how to interpret this, and whether there might be a somewhat more generous approach toward clients on receivables to present — to preserve, sorry, the top line growth.

Andrea Cangioli

executive
#23

Alright, thanks for the questions. Yes, that's correct. Our state division saw a modest revenue decline in Q2 relative to the same quarter in 2022. The main reason is a single account that reduced its market volume, and that account ties to sales of <<inaudible>>. Broadly speaking, the aesthetic trend remains stronger. It will stay smoother — lighter, let's say — than last year because of this one account. Outside that, we don't have particular issues in the rest of the world. We've run into more difficulties than previously, particularly across Middle Eastern countries, where some nations are struggling more than before to obtain currency with which to pay us, even though demand would have been more solid. So in short, the trend we project for the second half is roughly consistent with the first half. Whether we land somewhat above or somewhat below 2022 will hinge on specific trends. We are missing one very significant account here. For...

Giovanni Selvetti

analyst
#24

Apologies for that — but when you say a big account, what kind of weight are we actually talking about?

Andrea Cangioli

executive
#25

Yeah. That's an account that's waiting on a handful of percentage points. Definitely, we aren't seeing growth in the double digits. I mean, excluding this account, double-digit growth wouldn't have shown up for us, since we took a loss on it, plus there was smoother behavior from the Middle Eastern country and, in some way, from the U.S. countries as well. This is going to carry on. And I mean, the trend will hover around parity with 2022 during the second half. As I mentioned in my presentation, unlike the 2022 situation, when our order books were huge, orders now arrive in a more regular fashion, yet they don't pile up into enormous backlogs. So our visibility is lower than it was in 2020. Still, we're extremely optimistic, because the launch of new products has also stimulated the market, and we've witnessed good results when it comes to order acquisition, which, I mean, look very promising for the end of the year. Actions in China. As I said, various actions are being taken — when Enrico said the employee count went up, that's a technical increase: we acquired a company, and that company we acquired had 80 employees on December 31.

Andrea Cangioli

executive
#26

So if you compare June 30 with December 31, this company has simply been added in. That doesn't mean we hired new people at the other companies that are struggling. KBF, which works on the electrical factories for batteries for electrical vehicles, is doing decently, in line with the plan, while the one that is struggling is the ship metal business, where we didn't hire and where we also started, let's say, a review, which could end -- which is going to end up with some head count reduction as well. But note, the problem I highlighted is that we have a margin production. That means we are manufacturing more or less the same volume as last year. So in terms of production, we didn't manufacture fewer laser systems. We simply had to bear lower prices on those base systems. And part of the lower price is absorbed by the reduction in cost, but not in full, and this ends up in the reduction of margin. So the design and the sales network reorganization is one of the main topics in our organization work. We are working in order to have the export part. Export from China is dedicated to the neighboring country and in minor part to the Western countries, but also this export part had great problems in its management during the lock down.

Andrea Cangioli

executive
#27

So at this point we're reorganizing the distribution network—in India, for example, and also in Thailand and Korea—which during the lockdown year simply couldn't get the attention it needed. We've also observed that even where volumes are holding roughly steady, there's no growth happening. And thanks to upgrading our production capacity and, sorry, thanks to better organization of our production facilities, we were able to cut down on the plants we operate, which lowers cost. Those are the key steps we're taking. As for the Chinese business's financial result for the period, on EBITDA and on EBIT Velos—hold on, let me verify in the figures—it came to approximately EUR 4 million. So EBITDA, and unlike last year, they were profitable. The effect has been substantial. Naturally, you should keep in mind that about EUR 1 million, I believe, is a non-cash expense for assigning stock to employees. That is, stock-based compensation, which is real under IFRS accounting but does not represent an actual cost.

Andrea Cangioli

executive
#28

On the financial position — yes, you've got it right, exactly right. The world is shifting now. We no longer face the hassle and those long lead times. But this is where we stand today, and things are beginning to change as of the first months of 2023. What we're commenting on now is the first 6 months of 2023. And then, as I said, the trend has been shaped by what was done in 2022 and in early 2023. Today I see precisely what you're describing. We're cutting purchases because we have materials in-house. We're also working to return to more standard payment terms with vendors, and we're optimistic. We believe these steps will lead to a rise in the net financial position and a reduction of cash absorbed by the increase of net working capital. As for your suggestion to be somewhat more generous with customers so as to boost sales volume — regarding payment terms with customers, I'm certainly with you on it. We have to strike a balance, because there's also a risk involved, and it isn't only a financial variable. In several cases we don't have counterparts that are extremely solid financially; we're not necessarily able to obtain protection through letters of credit or warranties offered by supranational bodies or national bodies like the ones we have in Italy.

Andrea Cangioli

executive
#29

In Italy there's a government body known as SACE that can insure our receivables in certain countries. So when I extend more credit to a customer, I have to be sure that customer will be capable of paying. So that's a factor we're weighing, but expanding receivables is not something we want to do, since we don't want bad debt to rise in the years ahead. I hope that answers your...

Giovanni Selvetti

analyst
#30

Understood, understood. So you're not really seeing any kind of rise in accruals — say, for trade receivables, or something like write-offs?

Andrea Cangioli

executive
#31

That issue isn't with us anymore. Our challenge looks somewhat different. What's shifted in the business is that back in June 2022, our finished goods inventory stood at 0, because the moment anything reached the delivery area, a buyer was already there to pay for it and take it. These days, customers are no longer willing to pay just to get the materials out the door, and collecting the payments so we can deliver the scheduled program has turned into more of a struggle. That's how our way of working looked all the way up to 2019. And as I said earlier, we're seeing a kind of normalization. Things are going well, but the hype generated over the past COVID couple of years is now settling into a good sales trend, though a normal — a normal relationship with customers. And in our world, a normal customer relationship means the customer holds off until the very last moment before paying for its deliveries.

Giovanni Selvetti

analyst
#32

Alright, Andrea, I don’t want to take up too much of everyone else’s time. Thanks so much.

Bianca Fersini-Mastelloni

unknown
#33

And as for the second question, we have — <<inaudible>> — go ahead, Marco, please.

Analyst

analyst
#34

First off, could you give us the EBITDA margin on sales for each division — that is, for the Medical segment and for the industrial segment, if that's possible. Second, on discount policies: I recall from the last meeting you said you hadn't raised prices, but you had halted discount policies for your customers. So I'd like to know whether you've begun to bring back any discount policies for customers in order to boost revenue on volumes. And my last question concerns the backlog. You already indicated that visibility on the year is reduced. But can you tell us more about the backlog for the end of the year. I mean, do you have any forecasts on that? And is it possible to get some numbers.

Andrea Cangioli

executive
#35

On segment EBITDA, we have never disclosed an adverse, and that's a permission that hasn't ever been available. It's possible we'll make it available down the road. Broadly, since we have — and overall, with a 13.2% EBITDA margin, you need to keep in mind that the EBIT margin is considerably higher. In the medical field, the EBITDA margin is considerably higher than in the industrial field. We typically report on an EBIT basis, where, I mean, we have total — excuse me, 11.2% EBIT margin; bear in mind that the EBIT margin in medical is south of 20%, whereas starting this year, in which we did poorly on industrial margin, the Industrial EBIT margin is south of 2% in terms of order of magnitude and in terms of proportion. As a standard operating level, what I told you about medical is what we currently operate, while the EBIT margin I just mentioned, below 2%, is something deeply affected by the very full performance of a Chinese facility; a more normal EBIT margin for that division would be, let's say, south of 10%. We never reached 10% in that particular business. But we never gave detailed reporting, and we just gave rough numbers concerning price increase related to volume increase and discounts, as you remember well; the point was that in the Medical business, we — where prices are usually stable over the time.

Andrea Cangioli

executive
#36

At the end of 2022, we rolled out price increases across a number of product lines. Those increases were only partly absorbed, partly not. Obviously, putting a price increase through in a market that's very, very strong and buoyant, like the one we enjoyed throughout 2022, is one thing. Doing it now, when conditions remain decent but are normalizing, is quite another. So I'd say the 10% price increase ultimately touched roughly 30% of our sales. In Industrial, things work differently, since the fast decline in cost of goods sold across most of production has meant the price level has trended downward over time. So there, instead of raising prices, we held the price level steady, and we ceased granting discounts and modern discount, bringing the price list down year-over-year. But in the industrial business, on the price level, 2 trends are shaping how the business is evolving from this standpoint. In the Western world, production of <<inaudible>> is moving toward a higher average number of kilowatts sold per system, which drives the system's cost up and therefore pushes prices higher. And beyond that, we're growing the count of systems sold into international markets, where prices also tend to run above those in Italy, where the market is highly competitive.

Andrea Cangioli

executive
#37

Also in this instance, we eventually see prices rise because of the mix, even though for every product at each price level, pricing remains stable. Lastly, regarding what we hold in hand for order books at year-end, we never reveal the size of the order books. In prior years, we said our order book visibility was typically 60 days. During 2022, we reported that the order book was expanding to a size never seen before. And at certain points, I believe we had order books covering, depending on market segments, 4 to 6 months. Now, particularly in medical, we are returning to the more normal 60 to 90 days of order coverage. That is why the forecast we produced for the end of the year, which underpins the guidance stating that we will slightly increase overall sales volume in 2023 versus 2022, is backed by the current order books. But we do not disclose, and never disclose, any specific figure on our order book, I'm sorry.

Bianca Fersini-Mastelloni

unknown
#38

Andrea. Our next question is from Benjamin <<inaudible>> of <<inaudible>>.

Analyst

analyst
#39

Yes. I have a couple of quick questions. My first one concerns the laser coating business and how profitable that subsegment is. If I got it right, you mentioned earlier that EBIT went from EUR 6 million down to minus EUR 1.1 million in H1, if I heard correctly, but you also referred to an EBIT loss of EUR 4 million during this Q&A. Sorry, I got a bit confused. So could you please repeat the impact that the weak laser-cutting business in China had on EBIT? I would appreciate that. And also the reason behind this margin drop — is it only the pricing pressure you mentioned that explains this margin drop? Or were there also some, I don't know, initial recruitment and capacity investments in China, which led to another assumption of OpEx? And what about the other markets, Italy, the Americas in the industrial sector — were they not able to compensate a little bit? I mean the weaker China. Second, on the currency impact in H1 '23, if you could give us, let's say, a rough figure for the currency impact on EBIT margin, because I have in mind that last year in '22, there was a very favorable FX impact on profitability?

Analyst

analyst
#40

Third question: how do you see H2 shaping up for the industrial sector as a whole? It came in at minus 5% in Q2 versus plus 12% or 13% in Q1. So should we be bracing for a sharper decline in Q3, or is a minus 5% to minus 10% a reasonable assumption at this point for H2 in industrials?

Andrea Cangioli

executive
#41

On the cutting side — sorry, I didn’t make my position clear, and I apologize for that. For the first 6 months, the cutting division’s EBIT was positive at about EUR 1.1 million, down from last year’s EBIT. EUR 1.1 million, roughly; ski is the next result at plus 5, minus 4%, last 5, Italy and Brazil, minus 4% China. So really, what happened is exactly what you said: Cutlite Penta’s excellent performance offset the losses in China. The results were positive nonetheless. But of course, they would have been much better if China had performed decently. On the weak performance in China, yes, I confirm there are no extraordinary expenses, apart from the 1 million in stock-based compensation, which isn’t extraordinary — it simply would need to be adjusted in a pro forma financial report that doesn’t take into account the IFRS adjustment. But the main issue is that with stable sales volumes in terms of number of products sold, there is a decrease in average price and a decrease in margin because we are unable to reduce our cost of goods sold proportionally to the reduction in prices.

Andrea Cangioli

executive
#42

Okay, so that's really the core issue. That's the area we need to focus on, and we are focusing on it — we're reducing OpEx, but the bigger push is improving marginal sales by finding wealthier markets and trying to streamline production better while bringing down cost of goods sold. Currency — you've got a good memory there. It hit hard in 2022, since the U.S. dollar's value jumped suddenly. That isn't happening in 2023. Across the first 6 months, most currencies are essentially flat. Margins aren't affected. Only one currency moved meaningfully, and that's the Chinese renminbi — its average exchange rate for the first 6 months of 2023 rose compared with the rate during the first 6 months of 2022. In this case there's a 5.7% increase, though it doesn't hit margin, because with the renminbi it's largely a translation effect, given that costs of sales in Revenue are mostly denominated in renminbi too. As for your final question, on what we expect from the industrial business in the last quarter — since within the overall industrial business we recorded a sales decline in the second quarter.

Andrea Cangioli

executive
#43

In the industrial business, I don't think we're going to hit that very sharp overall increase we've been anticipating, since China is underperforming. On top of that, we'll be up against a lighter benchmark in China during the second half, given how poorly China performed starting in Q3 2022. So depending on how China does, I think we'll see either a modest rise or a modest decline, but at this point we're not in a position to pin down a number. On the whole, I expect we'll finish the year roughly flat on revenue, or with a slight uptick consistent with the overall guidance. I'd also like to note, from this standpoint, that cutting business isn't the only business within our industrial invented business, although it's worth roughly 80% or 75%, I believe, in the first half of 2023. We anticipate a very strong showing from the marketing business as well as from the Laser source business. Those are smaller markets, which I believe together amount to something like EUR 40 million in revenue across the year. But we think that in that market, within these divisions, the sales amount will grow, delivering good results in 2023 compared with what we managed to do in 2022.

Bianca Fersini-Mastelloni

unknown
#44

And we have another question, this time from Andrea Randone at Intermonte.

Andrea Randone

analyst
#45

I've got a question about new products. I mean, this year, you already said the pipeline was somewhat weaker during the first half, though perhaps stronger in the second half. So, following a general comment, I'm wondering whether you could say a few words about the acne solutions and what's happening with those in the U.S. And the final point is always about new products. I mean, your results in urology are very good. I mean, is there anything new in that segment as well? Usually, it was a very profitable segment, so again, if you could spend a few words on it.

Andrea Cangioli

executive
#46

Thank you, Andrea — this gives me a chance to say a few words about new products, something this presentation, being more focused on the financial side, didn't really have room for. New products are live, or they're the foundation of what our product development does. We've got meaningful new products in the pipeline. As you recall well, 2022, along with the goods purchases that raised our inventory, was also marked by the necessity to redesign — to redesign a number of products, and R&D and engineering were tied up with redesigning instead of designing new products, but it was a swim or zinc. Had we not been able to redesign certain aspects of the products, we would not have been in a position to deliver. And at this point we're back to the customary brilliant productivity of our R&D department. We mentioned — I already mentioned during the presentation, the launch of the drop platforms, the protractors launched at the world-dermatology congress in Singapore in July; those platforms represent an improvement of the gain, which is our flagship platform for her removal of the Honda, or flagship platform in body shaping, and of breadth, our flagship platform in the treatment of pigmented lesion and in the tightening of the scheme. Those incremental improvements, jointly with economic improvements on the system, are — radically change those systems and have also already brought a wave of new purchase orders for these new devices.

Andrea Cangioli

executive
#47

We also have some very important new products made specifically for the U.S. market. Today, a very important customer of ours is visiting our production sites, and we will have a new bond shaping device built on the new technology, which will be brought to market as soon as we get the clearance to sell it in the United States. That should happen sometime within the end of the year. And this product, called physic 160, really could change the game in the market. Lastly, still on static, we are deeply — we are closely in discussions with the large accounts, which was missing when I answered Mr. Giovanni Selvetti's question earlier, in order to redefine the product and to have a new wave of orders in 2024. So I would like to say that we feel extremely strong and fully confident in our ability to have a very strong pipeline and to attract customers with new products. Acne. Acne is a home turn project. For the first time, in the 6 months, we have an amount larger than 0 in the sales of a cure system. It's something very small because we are talking about the preliminary launch which is currently being carried out by our U.S.

Andrea Cangioli

executive
#48

The company is accurate, but after several years we are finally seeing something move—finally, something has moved. The company <<inaudible>> funded in order to start, which with this initial product launch. This is what we are supporting, and we are confident that sales volumes will stay low but constant over the next 6 months, upon success of the clinical results in terms of market results of the first unit installed to work on the market, because I need to recall that up today—up to now, we were basically working with Luminare all. So we didn't have the system working on the market. Upon the expected positive results, accuracy should be able to finally start its launch program, which should take place in 2024. But it's too early now to define if and how large would build volume that they will be absorbing in 2024. About urology, you're right, we did extremely well. We do not have new breakthrough products, but we are redesigning products in order to improve also our penetration in the market also through our OEM partners. We enlarged the number of OEM partners, which rely on Quanta System for the Stone devices and also for the BPH devices.

Andrea Cangioli

executive
#49

There's a long-term project we have in the pipeline. That project is a complex one. For quite a while now, we've been discussing with you and with investors this new shortfalls laser, which ought to enhance how the current reference product performs — that being the fiber laser, the fiber laser product — yet it won't be on the market in the near term. Even so, we're fairly optimistic regarding how the markets will develop over the coming months. I believe that answers your question.

Bianca Fersini-Mastelloni

unknown
#50

Andrea. Our next question is from Emmanuel de Figueiredo at LBV — go ahead, Emmanuel. Emmanuel? Are you still with us? No. All right. We'll hand things over to Andrea Bonfa from Banca Akros.

Andrea Bonfà

analyst
#51

First off, on your initial question about potential cash in H2 — you said you're working to recover part of the X stock. Is it possible to put a number on that, given that in the first half you saw EUR 16 million in net working capital? Second, on that same point: in a scenario where sales growth is, say, slowing down, do you expect to turn into more of a cash-generating machine, or do you still expect working capital to keep absorbing cash and not let you generate it properly? That's more of a longer-term question. The other one is about the industrial laser. If you could elaborate on how it's performing in Brazil and the U.S., in particular when the U.S. will become visible in the later — in the industrial laser business. And if I may look at your Q2 '23 figures, it seems both Italy and the rest of Europe slowed down quite materially — if you can elaborate on those market aggregates for H2 '23.

Andrea Cangioli

executive
#52

You asked about what's anticipated to bring down the general economy, and whether it's a particular market segment — I wasn't able to hear that.

Andrea Bonfà

analyst
#53

I missed part of what you asked, but if I got it right, I was talking about the situation where your sales growth rates are decelerating. So they're no longer what they were in the recent past. If you're turning into a cash unit machine, because I mean previously, the growth we saw from a net working capital perspective. So I'm asking whether, in a more stable scenario, you ought to turn into a cash ninth machine. So I'd like to hear your view on that.

Andrea Cangioli

executive
#54

Alright, let me begin with the first question. How much we intend to recover is hard to pin down, since it hinges on a number of factors. We're carrying excess stock — that much is clear. The bulk of that specific inventory has already been paid for. So selling it down would turn us into quite a strong cash generator, because we'd be moving goods that are already paid for. That said, there are 2 uncertainties. The first is how deep demand runs — more or less, we have a sense of how much we'll sell. But the bigger one is the price we'll get for any given product, because what's hurting us is our enormous breadth of products, which is a major competitive advantage but also a big generator of stock inventory, since you must plan large volumes to hold safety stock for every product line. So if the excess stock across each product line gets released evenly, it's fairly logical that we will be — we should be — in a position to free up roughly EUR 20 million of inventory by here at the end of the year. I don't believe that will happen. I don't believe that will happen, because we'll be able to fully release certain lines, but some of the lines will stay where they are.

Andrea Cangioli

executive
#55

Also, during this period we'll be buying additional materials for other product lines. Naturally, looking at our financials for the first 6 months, we aren't a cash generator. Yet now that we're paying for all this material, I believe that, since we won't be raising volume that much and won't need to over purchase the way the contingency of 2022 forced us to, we believe — we will go back to being a good cash generator, just as we were previously. So — I can't give you the exact number, but I can confirm that the trend is the right trend. Was there another question?

Andrea Bonfà

analyst
#56

Brazil, together with the U.S., is where we see industrial laser demand, and Europe — Italy in particular — is industrial as well.

Andrea Cangioli

executive
#57

Brazil, I can give you the precise numbers for Brazil — hold on just one moment. In Brazil they achieved, in the low — one second on that. I don't — so I have to locate it.

Enrico Romagnoli

executive
#58

For Brazil, Q2 sales rose 5%. Over the 6 months, our sales were up 2%.

Andrea Cangioli

executive
#59

Right. So in Brazil, sales are rising a bit, though not by much. The biggest gains came in Italy and in the other countries; in the U.S. as well, the figure is climbing, but revenue there isn't worth calling out at this point. We have high hopes for the U.S. down the road, and we'll likely start disclosing those numbers going forward, because — as I told you earlier — this is the second time we've planned the trader, and we're seeing enormous success at this trade fair, since we already have in place the initial scale of an effective distribution network in the United States. We expect to see solid sales results in the U.S. market as early as 2023, with further growth in 2024. As for sales in Italy and Europe, we will — we're planning to see a broader increase in Europe and a steadier trend in Italy, given that the incentives for the 4.0 are still there but aren't as compelling as they used to be. And so demand in Italy will not, in the end, exceed the performance of 2022 in 2022.

Bianca Fersini-Mastelloni

unknown
#60

Andrea, our list doesn’t show any further questions. I’d like to check with the floor and see whether anyone else has a question.

Andrea Cangioli

executive
#61

I have had the chance to meet with Emmanuel.

Bianca Fersini-Mastelloni

unknown
#62

Emmanuel appears to have exited the conference. Are there any further questions from the floor? There are none. So, with no additional questions remaining, we'll bring this conference to a close. Should you have anything else you'd like to look into, feel free to reach out to Enrico Romagnoli — he'll be glad to answer whatever you ask. Thanks for joining this conference, and we hope to see all of you again next time. Good afternoon, everyone. Bye. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.